Classification of <scp>PD‐L1</scp> expression in various cancers and macrophages based on immunohistocytological analysis-Reference-Cited by-同舟云学术

Classification of PD‐L1 expression in various cancers and macrophages based on immunohistocytological analysis

Published:2022-06-15 Issue:9 Volume:113 Page:3255-3266
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Saito Yoichi¹²³⁴^ORCID,Fujiwara Yukio¹^ORCID,Shinchi Yusuke¹⁵,Mito Remi¹⁶,Miura Yuji¹⁷^ORCID,Yamaguchi Tomoya⁸^ORCID,Ikeda Koei⁵,Urakami Shinji⁹,Nakashima Yuta³^ORCID,Sakagami Takuro⁶,Suzuki Makoto⁵,Tabata Yasuhiko²,Komohara Yoshihiro¹^ORCID

Affiliation:

1. Department of Cell Pathology, Graduate School of Medical Sciences, Faculty of Life Sciences Kumamoto University Kumamoto Japan

2. Laboratory of Biomaterials, Institute for Frontier Life and Medical Sciences Kyoto University Kyoto Japan

3. Laboratory of Bioengineering, Faculty of Advanced Science and Technology Kumamoto University Kumamoto Japan

4. Japan Society for the Promotion of Science Tokyo Japan

5. Department of Thoracic Surgery, Graduate School of Medical Sciences, Faculty of Life Sciences Kumamoto University Kumamoto Japan

6. Department of Respiratory Medicine, Graduate School of Medical Sciences, Faculty of Life Sciences Kumamoto University Kumamoto Japan

7. Department of Medical Oncology Toranomon Hospital Tokyo Japan

8. Department of Cancer Biology, Graduate School of Medical Sciences, Faculty of Life Sciences Kumamoto University Kumamoto Japan

9. Department of Urology Toranomon Hospital Tokyo Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15442

Reference37 articles.

1. PD-1 and PD-1 ligands: from discovery to clinical application

2. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages

3. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

4. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

5. The blockade of immune checkpoints in cancer immunotherapy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch‐repair deficiency;The Journal of Pathology;2024-02-16

2. The role of programmed death receptor (PD‐)1/PD‐ligand (L)1 in periodontitis and cancer;Periodontology 2000;2024-02-13

3. IL-32 production from lung adenocarcinoma cells is potentially involved in immunosuppressive microenvironment;Medical Molecular Morphology;2024-02-06

4. Pathogenicity of functionally activated PD-1+CD8+ cells and counterattacks by muscular PD-L1 through IFNγ in myositis;Journal of Autoimmunity;2024-01

5. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer;Pathology - Research and Practice;2023-04